Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.67 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | KIT | P10721 | 11/20 | 0.57 |
| ▸ | CSF1R | P07333 | 10/20 | 0.57 |
| ▸ | BRAF | P15056 | 4/20 | 0.56 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7606215 | 0.93 | HPGDS (0.60) | HPGDSSLC2A1KITCSF1RBRAF | |
| SCHEMBL6782706 | 0.91 | HPGDS (0.75) | HPGDSKITCSF1RBRAFBTK | |
| SCHEMBL7681667 | 0.90 | HPGDS (0.63) | HPGDSSLC2A1KITCSF1RBRAF | |
| SCHEMBL7677867 | 0.90 | HPGDS (0.66) | HPGDSKITCSF1RBRAFBTK | |
| SCHEMBL31721202 | 0.88 | HPGDS (0.69) | HPGDSKITCSF1RBRAFBTK | |
| SCHEMBL6973506 | 0.88 | HPGDS (0.64) | HPGDSKITCSF1RBRAFEGFR | |
| SCHEMBL6976773 | 0.88 | HPGDS (0.67) | HPGDSKITCSF1RBRAFBTK | |
| SCHEMBL6966564 | 0.87 | HPGDS (0.65) | HPGDSKITCSF1RBRAF | |
| SCHEMBL6978632 | 0.86 | BRAF (0.70) | HPGDSKITCSF1RBRAFEGFR | |
| SCHEMBL6777741 | 0.86 | HPGDS (0.64) | HPGDSKITCSF1RBRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | claimed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | claimed |
| EP-1017378-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2002-12-11 | — | — | EP | claimed |
| JP-2001517620-A | — | — | 2001-10-09 | — | — | JP | claimed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | claimed |
| US-6686467-B2 | INHIBITORS OF THE PRODUCTION OF CYTOKINES SUCH AS TUMOUR NECROSIS FACTOR (HEREINAFTER TNF), FOR EXAMPLE TNF ALPHA , AND VARIOUS MEMBERS OF THE INTERLEUKIN (HEREINAFTER IL) FAMILY, FOR EXAMPLE IL-1, IL-6 AND IL-8 | ZENECA LIMITED (GB) | 2004-02-03 | — | — | US | disclosed |
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED | 2003-09-04 | — | — | US | disclosed |
| US-6498274-B1 | Amide derivatives for the treatment of diseases mediated by cytokines | ZENECA LIMITED (GB) | 2002-12-24 | — | — | US | disclosed |
| EP-1017378-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2002-12-11 | — | — | EP | disclosed |
| EP-1017378-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | AstraZeneca UK Limited (GB) | 2000-07-12 | — | — | EP | disclosed |
| WO-1999015164-A1 | AMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ZENECA LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166730-A1 | Amide derivatives for the treatment of diseases mediated by cytokines | IL2, IL6, IL6ST | HPGDS 131/4885SLC2A1 3494/4885KIT 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.